TrialBMC cancer2015
Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial.
Tetsuya Fujimura et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this papercites it